mRNA and Delivery / Lipids and LNP Excipients
ALC-0159
Quick view. ALC-0159 (CAS 1849616-42-7) is listed for identity-scoped inquiry through OROGO. Current availability, exact chemical form, specification and packaging are confirmed for each request; this listing makes no stock or suitability claim. The PEG-2000 wording is a nominal identity descriptor; it does not establish a fixed molecular weight or repeat-unit count. Catalog target purity: Specification by inquiry. Availability: Inquiry only — contact OROGO to confirm current availability.
Request a quote Review request checklist
Structure
Structure note. Because the repeat count varies, this drawing does not define an exact molecular formula, molecular weight, PEG distribution or lot composition.
Catalog status
Scope. "Available for inquiry" is not a stock claim. Operating tier is a catalog-merchandising priority. Development phase and program context are shown only where the reviewed catalog source provides a mapping; they describe the chemistry platform and do not claim that OROGO supplies the named program.
| Supply status | Available for inquiry |
|---|---|
| Operating tier | Core |
| Reviewed supporting program count | 1 |
| Representative chemistry-platform program | tozinameran (Comirnaty) |
| Highest development phase | Marketed |
| CAS status | Published registry number |
Product profile
ALC-0159 is classified as mrna and delivery / lipids and lnp excipients.
ALC-0159 is supplied for research use within the PEGylated Amphiphiles product family.
For ALC-0159, confirm the current specification, storage conditions and downstream-method compatibility before routine use.
Names and search terms
Confirmed or normalized name variants
- 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide
Useful catalog search terms
- 1849616-42-7
- ALC-0159 / 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide
Physicochemical data
| Reviewed identity | ALC-0159 / 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide |
|---|---|
| Nominal PEG designation | PEG 2000 |
Release documentation
The current specification defines the analytical method and acceptance criteria; the released lot result is reported on the CoA.
Additional HPLC, MS or NMR documentation can be agreed during technical review where available.